Shanghai-based EpimAb Biotherapeutics has entered into a strategic license agreement with Spanish pharmaceutical company Almirall for the development of bispecific antibodies (BsAbs) against up to three undisclosed target pairs. This partnership marks a significant step in leveraging EpimAb’s innovative Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to generate BsAbs, with Almirall securing exclusive global development and commercial rights.
Deal Financials and Milestones
Under the terms of the agreement, EpimAb will receive milestone payments totaling up to USD 210 million, in addition to royalties on future net sales. This financial arrangement underscores the potential value of the BsAbs in the global market, particularly in the field of medical dermatology. Further financial details of the agreement were not disclosed, maintaining a focus on the scientific and therapeutic potential of the collaboration.
Focus on Medical Dermatology
Almirall, a global biopharmaceutical company with a focus on medical dermatology, aims to utilize the BsAbs sourced from EpimAb to target immunology areas linked to dermatological conditions. This strategic move is expected to enhance Almirall’s portfolio in the dermatology space, offering new treatment options for patients suffering from various skin conditions.-Fineline Info & Tech
